Polaris AI Pharma Corp. (KOSDAQ: 041910)

Market Cap	75.58B
Revenue (ttm)	63.94B
Net Income (ttm)	989.48M
Shares Out	13.28M
EPS (ttm)	84.72
PE Ratio	67.17
Forward PE	n/a
Dividend	100.00 (1.73%)
Ex-Dividend Date	Dec 27, 2024

Volume	12,790
Average Volume	20,015
Open	5,780.00
Previous Close	5,780.00
Day's Range	5,660.00 - 5,800.00
52-Week Range	4,810.00 - 12,300.00
Beta	0.75
RSI	50.30
Earnings Date	Mar 21, 2025

About Polaris AI Pharma

Polaris AI Pharma Corp. engages in the manufacture and sale of pharmaceuticals products in South Korea and internationally. It also offers its products for various therapeutic categories, such as diagnostic acid, antidiabetic, anti-depressants, and cholinergic. The company was formerly known as EstechPharma Co., Ltd. and changed its name to Polaris AI Pharma Corp. in March 2024. The company was founded in 1996 and is headquartered in Hwaseong-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 1996
• Employees: 160
• Stock Exchange: KOSDAQ
• Ticker Symbol: 041910

Financial Performance

In 2021, Polaris AI Pharma's revenue was 60.40 billion, a decrease of -1.51% compared to the previous year's 61.32 billion. Earnings were 6.87 billion, a decrease of -56.30%.